Clinical Trials Logo

Cough clinical trials

View clinical trials related to Cough.

Filter by:

NCT ID: NCT02993822 Completed - Clinical trials for Chronic Refractory Cough

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Start date: May 22, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.

NCT ID: NCT02981147 Completed - Cough Clinical Trials

PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough

PEACe
Start date: March 14, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the efficacy of Phytus in Acute Cough

NCT ID: NCT02932397 Completed - Elective Surgery Clinical Trials

Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane

PROPOREV
Start date: October 2016
Phase: N/A
Study type: Interventional

Emergence of general anesthesia is a critical period, in the same way as the induction of anesthesia, during which several adverse events may occur. Extubation may even be more difficult than the intubation, with a higher respiratory complications rate. Among these, cough is common and expected. It can be associated with significant complications including hypertension, tachycardia, increased intracranial pressure, bleeding at the surgical site or even wound dehiscence. The incidence of coughing during emergence of general anesthesia varies depending on the type of airway instrumentation, the population under study, agents used for the maintenance of the anesthesia and techniques used to prevent coughing. In the literature, the incidence of coughing during emergence of general anesthesia under endotracheal intubation varies from 38 to 96%. In our center, the incidence of coughing during emergence of general anesthesia under desflurane and endotracheal intubation is 30 % according to a local preliminary study. Propofol is well-known to inhibit airway reflexes. Total intravenous anesthesia (TIVA) is associated with a lower incidence of coughing compared to inhalated anesthesia. The efficacy of propofol at a subhypnotic dose to reduce coughing during emergence has recently been demonstrated in patients undergoing nasal surgery under sevoflurane. However, the most effective antitussive dose remains unknown and its efficacy during anesthesia under desflurane has not yet been demonstrated. Propofol is rapidly available, simple to administer and has an interesting pharmacological profile, among others due to its short half-life. The aim of this study is to evaluate if an intravenous bolus of 0.5 mg/kg of propofol is more effective than placebo administration to decrease the incidence of coughing during emergence of general anesthesia under desflurane (PROPOREV). Propofol could also reduce the incidence of postoperative nausea and vomiting (PONV).

NCT ID: NCT02882555 Completed - Cough Clinical Trials

Effect of Muscular Exercise on Cough Reflex

REFLEXE TOUX
Start date: June 2012
Phase: N/A
Study type: Interventional

The hypothesis is that the cough reflex induced by capsaicin is inhibited during exercise. The purpose of this study is to determine if a short muscular exercise inhibits the cough reflex induced by capsaicin inhalation.

NCT ID: NCT02797756 Completed - Clinical trials for Gastroesophageal Reflux (GER)

Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough

Start date: August 5, 2014
Phase:
Study type: Observational

Using an active cohort of children in whom Airway and gastrointestinal endoscopy will be performed, investigators will conduct a chart review to obtain relevant clinical data and the investigators will use an aliquot of airway sample obtained during the clinically indicated bronchoscopy for microbiome analysis. A case-control study design will be used to study whether subjects with CC with GER have a distinct lung microbiome and increased inflammation as compared with subjects with CC without GER and to determine whether the microbiome and degree of inflammation is related to the type of GER (acidic versus nonacidic).

NCT ID: NCT02711904 Completed - Cough Clinical Trials

Concentrations of Remifentanil for Extubation

REMEX
Start date: January 2011
Phase: Phase 4
Study type: Interventional

Condition of the State: (terminated, recruiting, etc.) Terminated Study Design: Main Objective: Compare the frequency and intensity of coughing at the time of extubation with two infusions of remifentanil that predict a plasma concentration (PC) of 3 - 4 and 2 - 3 ng/ml, through the technique of target controlled anesthesia

NCT ID: NCT02632851 Completed - Cough Clinical Trials

Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution

Start date: December 2015
Phase: N/A
Study type: Observational

This observational, non-interventional multicentric study compares the inhalation therapy on patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin inhalation solution and Pari NaCl (0.9%) inhalation solution

NCT ID: NCT02612623 Completed - Clinical trials for Refractory Chronic Cough

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

Start date: December 17, 2015
Phase: Phase 2
Study type: Interventional

This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.

NCT ID: NCT02612610 Completed - Clinical trials for Refractory Chronic Cough

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Start date: December 15, 2015
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency. The primary hypothesis for this trial is that at least one dose regimen of gefapixant is superior to placebo with respect to the mean change from baseline in awake cough frequency (on the log scale).

NCT ID: NCT02572375 Completed - Cough Clinical Trials

Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study

COGUSS
Start date: October 2014
Phase: Phase 1
Study type: Interventional

The objectives of this pivotal study are: 1. to evaluate bioavailability of an extended-release and immediate release Codeine Phosphate/Guaifenesin tablet at steady state following multiple oral administration 2. to assess the safety and tolerability of this Codeine Phosphate/Guaifenesin extended release formulation.